AbbVie Inc. (ABBV)
Betting Big On AbbVie: A Prescription For Growth And Dividends
AbbVie Inc. has rebounded from setbacks with a strong pipeline, including the promising Parkinson's drug Tavapadon, which shows blockbuster potential. Key growth drivers like SKYRIZI and RINVOQ are boosting sales, while AbbVie maintains leadership in immunology and diversifies beyond Humira. With a 3.7% yield, steady dividend growth, and strong earnings recovery, ABBV stock offers attractive value and long-term upside potential for investors.
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.
AbbVie's third successful Parkinson's trial sets the stage for an eventful 2025
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson's disease on Monday and said it's on track to seek approval for the drug from the Food and Drug Administration in 2025.
Don't Miss The Dividend Train: 2 Top Buys To End 2024
Time in the market generally beats timing the market. This can be enhanced by buying low and selling high. Here's how. Being an active investor, I believe that timing individual equities can complement the strategy of staying consistently invested. You're timing stocks, while staying in the market. The Dividend Train concept emphasizes the importance of timing when buying dividend stocks to maximize income and compound growth.
AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study.
AbbVie Inc. (ABBV) Citi's 2024 Global Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV ) Citi's 2024 Global Healthcare Conference Call December 3, 2024 10:15 AM ET Company Participants Jeffrey Stewart - Executive Vice President and Chief Commercial Officer Roopal Thakkar - Executive Vice President, R&D and Chief Scientific Officer Scott Reents - Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham - Citigroup Geoff Meacham Morning sessions. I'm Geoff Meacham.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (^GSPC 0.24%) index rose a whopping 57.1% higher.
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
What's better than receiving passive income? Enjoying it for decades.
Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report?
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?
My Best Dividend Aristocrats For December 2024
The ProShares S&P 500 Dividend Aristocrat ETF is up 10.26% year-to-date through October. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 40 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.
